EDEl-Hadj Driche

El-Hadj Driche

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


El-Hadj Driche has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In-vitro and in-silico antibacterial and antibiofilm activities of an aromatic heterocyclic metabolite from a novel halo-thermophilic Streptomyces sp. strain CBN-1 against bacteria causing nosocomial infections

    by El-Hadj Driche, Boubekeur Badji, Frédéric Pont, Abdelghani Zitouni

    Background Multidrug-resistant and biofilm-forming pathogens have become a global health challenge, contributing to persistent and hard-to-treat infections. The objective of this study was to characterize an active metabolite produced by a novel halo-thermophilic Streptomyces sp. CBN-1 that exhibits potent antibacterial and antibiofilm activities using a combined in-silico and experimental approach. Methods & results In this study, a halo-thermophilic Streptomyces sp. CBN-1 strain was selected for its ability to grow in 10% NaCl at 40 °C. This strain was identified using phenotypic characterizations and 16S rRNA gene sequence analysis as Streptomyces rochei NRRL B-2410 with 99.15% similarity. An active metabolite, CBNa-1, was extracted using n-butanol solvent from ISP2 broth medium and purified by HPLC. Structural characterization using electrospray ionization mass spectrometry and NMR spectroscopy identified CBNa-1 as an aromatic heterocyclic compound regulated by non-ribosomal peptide synthetase (NRPS) and type II polyketide synthase (PKS) genes. It exhibited potent activity with minimum inhibitory concentrations (MIC) ranging from 4 to 5 µg/mL and minimum biofilm inhibitory concentrations (MBIC50%) at ½ MIC. Additionally, in-silico docking analyses showed that CBNa-1 had stronger binding affinities from − 8.7 to −8.1 kcal/mol with isoleucyl-tRNA synthetase, glucosamine-6-phosphate synthase, penicillin-binding protein 1a, type II DNA topoisomerases, and quorum sensing compared to antibiotics (−5.7 to −7.9 kcal/mol). Furthermore, molecular dynamic (MD) simulation showed the stability of the protein-ligand complex under physiological conditions. Conclusion This study reports the first identification of CBNa-1, a metabolite from prokaryotic cells, with potent antibacterial and anti-biofilm properties to combat nosocomial infections caused by MDR pathogens, including bacteria resistant to third-generation cephalosporins.


  • Open Access

    Date extract as an alternative natural medium for cultivating Streptomyces sp. SA32 and enhancing its antifungal activity

    by Said Belghit, Boubekeur Badji, Andrea Vannini, El Hadj Driche, Zineddine Benbekhti, Abdelghani Zitouni, Noureddine Bouras

    Our study investigated the use of a natural medium, date extract, which has a low market value, to cultivate a bacterial strain that produces antifungal compounds. Strain SA32 was isolated by the method of suspension dilution using chitin medium from Algerian Saharan soil. Analysis of its 16S rRNA indicated that it belongs to the genus Streptomyces, showing a 99.52% identity with Streptomyces griseoflavus LMG 19344T. The kinetics of antifungal activity production on three solid media, date extract, ISP-2 (International Streptomyces Project-2), and Bennett, revealed that maximal production occurred on day 4 for ISP-2 and Bennett, and on day 5 for date extract. In broth media, maximal antifungal activities were observed on the 4th day of incubation for all three media. The average inhibition zones were larger in the date extract than in ISP-2 and Bennett, regardless of whether the medium was liquid or solid. The antifungal activity was detected only in the n-butanol fraction. HPLC analysis of the crude butanolic extract identified one fraction displaying activity against Aspergillus carbonarius. These findings indicated that the date extract can serve as a natural alternative to conventional culture media to produce Streptomyces sp. SA32 antifungals.

  • In-vitro antibacterial and antibiofilm activities and in-silico analysis of a potent cyclic peptide from a novel Streptomyces sp. strain RG-5 against antibiotic-resistant and biofilm-forming pathogenic bacteria

    by El-Hadj Driche, Boubekeur Badji, Florence Mathieu, Abdelghani Zitouni

    The proliferation of multidrug-resistant and biofilm-forming pathogenic bacteria poses a serious threat to public health. The limited effectiveness of current antibiotics motivates the search for new antibacterial compounds. In this study, a novel strain, RG-5, was isolated from desert soil. This strain exhibited potent antibacterial and antibiofilm properties against multidrug-resistant and biofilm-forming pathogenic bacteria. Through phenotypical characterizations, 16S rRNA gene sequence and phylogenetic analysis, the strain was identified as Streptomyces pratensis with 99.8% similarity. The active compound, RG5-1, was extracted, purified by reverse phase silica column HPLC, identified by ESI-MS spectrometry, and confirmed by 1H and 13C NMR analysis as 2,5-Piperazinedione, 3,6-bis(2-methylpropyl), belonging to cyclic peptides. This compound showed interesting minimum inhibitory concentrations (MICs) of 04 to 15 µg/mL and minimum biofilm inhibitory concentrations (MBICs 50%) of ½ MIC against the tested bacteria. Its molecular mechanism of action was elucidated through a molecular docking study against five drug-protein targets. The results demonstrated that the compound RG5-1 has a strong affinity and interaction patterns with glucosamine-6-phosphate synthase at − 6.0 kcal/mol compared to reference inhibitor (− 5.4 kcal/mol), medium with penicillin-binding protein 1a (− 6.1 kcal/mol), and LasR regulator protein of quorum sensing (− 5.4 kcal/mol), confirming its antibacterial and antibiofilm activities. The compound exhibited minimal toxicity and favorable physicochemical and pharmacological properties. This is the first report that describes its production from Streptomyces, its activities against biofilm-forming and multidrug-resistant bacteria, and its mechanism of action. These findings indicate that 2,5-piperazinedione, 3,6-bis(2-methylpropyl) has the potential to be a promising lead compound in the treatment of antibiotic-resistant and biofilm-forming pathogens. Graphical Abstract


  • Antibacterial and antibiofilm properties of two cyclic dipeptides produced by a new desert Streptomyces sp. HG-17 strain against multidrug-resistant pathogenic bacteria

    by El-Hadj Driche, Boubekeur Badji, Christian Bijani, Saïd Belghit, Frédéric Pont, Florence Mathieu, Abdelghani Zitouni

    Introduction The emergence of multidrug-resistant bacteria and biofilms requires discovering new antimicrobial agents from unexplored environments. Objectives This study aims to isolate and characterize a new actinobacterial strain from the Hoggar Mountains in southern Algeria and evaluate its ability to produce bioactive molecules with potential antibacterial and antibiofilm activities. Methods A novel halotolerant actinobacterial strain, designated HG-17, was isolated from the Hoggar Mountains, and identified based on phenotypic characterizations, 16S rDNA sequence analysis, and phylogenetic analysis. The antibacterial and antibiofilm activities of the strain were assessed, and the presence of biosynthetic genes (PKS-I and NRPS) was confirmed. Two active compounds, HG-7 and HG-9, were extracted butanol solvent, purified by HPLC, and their chemical structures were elucidated using ESI mass spectrometry and NMR spectroscopy. Results The strain HG-17 was identified as Streptomyces purpureus NBRC with 98.8% similarity. It exhibited strong activity against multidrug-resistant and biofilm-forming bacteria. The two purified active compounds, HG-7 and HG-9, were identified as cyclo-(d-cis-hydroxyproline-l-phenylalanine) and cyclo-(l-prolone-l-tyrosine), respectively. The minimum inhibitory concentrations (MICs) of HG-7 and HG-9 ranged from 3 to 15 μg/mL, comparable to the MICs of tetracycline (8 to 15 μg/mL). Their minimum biofilm inhibitory concentration (MBIC 50%) showed good inhibition from 48.0 to 52.0% at concentrations of 1 to 7 μg/mL against the tested bacteria. Conclusion This is the first report of cyclo-(d-cis-hydroxyproline-l-phenylalanine) and cyclo-(l-prolone-l-tyrosine) antibiotics from S. purpureus and their anti-multi-drug-resistant and biofilm-forming bacteria. These results indicate that both antibiotics could be used as effective therapeutics to control infections associated with multidrug-resistant bacteria.


  • A New Saharan Strain of Streptomyces sp. GSB-11 Produces Maculosin and N-acetyltyramine Active Against Multidrug-Resistant Pathogenic Bacteria

    by El Hadj Driche, Boubekeur Badji, Christian Bijani, Saïd Belghit, Frédéric Pont, Florence Mathieu, Abdelghani Zitouni

    Multi-resistant bacterial pathogens are a major public health problem for treating nosocomial infections owing to their high resistance to antibiotics. The objective of this research was to characterize the bioactive molecules secreted by a novel moderately halophilic actinobacterium strain, designated GSB-11, exhibiting a strong antagonistic activity against several multidrug-resistant pathogenic bacteria. This potential strain was identified by phenotypic, genotypic (16S rRNA), and phylogenetic analyses. GSB-11 was related to “Streptomyces acrimycini” NBRC 12736 T with 99.59% similarity. Molecular screening by PCR assay demonstrated that the strain possesses two biosynthetic genes coding for NRPS and PKS-II. Two active compounds GSB11-6 and GSB11-7 were extracted from the cell-free culture supernatant of Bennett medium and purified using reversed-phase HPLC. According to spectrometric (mass spectrum) and spectroscopic (1H NMR, 13C NMR, 1H-1H COSY, and 1H-13C HMBC) spectra analyses, the compounds GSB11-6 and GSB11-7 were identified to be maculosin and N-acetyltyramine, respectively. Their minimum inhibitory concentrations (MIC) revealed interesting values against certain multidrug-resistant pathogenic bacteria. They were between 5 and 15 mg/mL for GSB11-6, 10 and 30 mg/mL for GSB11-7. To our best knowledge, this is the first study of these active substances isolated from “Streptomyces acrimycini” showing an interesting antibacterial activity. Therefore, these essential compounds could be candidates for future research against multidrug-resistant bacteria.